Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with down syndrome and Alzheimer disease

Archives of Neurology

Volumn 68, Issue 11, 2011, Pages 1461-1466

  Sabbagh, Marwan N ^a,c   Fleisher, Adam ^b,c,e   Chen, Kewei ^b,c   Rogers, Joseph ^a,c   Berk, Camryn ^a   Reiman, Eric ^b,c   Pontecorvo, Michael ^d   Mintun, Mark ^d   Skovronsky, Daniel ^d   Jacobson, Sandra A ^a,c   Sue, Lucia I ^a,c   Liebsack, Carolyn ^a,c   Charney, Albert S ^a,c   Cole, Lauren ^a   Belden, Christine ^a,c   Beach, Thomas G ^a,c  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^d AVID RADIOPHARMACEUTICALS   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; CARBIDOPA PLUS LEVODOPA; DONEPEZIL; FLORBETAPIR F 18; MEMANTINE; NEUROLEPTIC AGENT;

ADULT; AGGRESSION; AGITATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOMATION; BEHAVIOR DISORDER; BRAIN CORTEX; CASE REPORT; COGNITIVE DEFECT; CORPUS STRIATUM; DOWN SYNDROME; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MENTAL DEFICIENCY; MYOCLONUS; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RADIOACTIVITY; THALAMUS; TREMOR; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; DOWN SYNDROME; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 81355154155     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.535     Document Type: Article

References (19)

1. Yaari R, Corey-Bloom J. Alzheimer's disease. Semin Neurol. 2007;27(1):32-41. (Pubitemid 46239037)
2. Mann DM, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci. 1989;89(2-3):169-179. (Pubitemid 19052948)
3. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology. 1985;35(7):957-961. (Pubitemid 15026265)
4. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998;150(2):296-304. (Pubitemid 28231961)
5. Evenhuis HM. Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR). J Intellect Disabil Res. 1996;40(pt 4):369-373. (Pubitemid 26317071)
6. Beacher F, Daly E, Simmons A, et al. Alzheimer's disease and Down's syndrome: an in vivo MRI study. Psychol Med. 2009;39(4):675-684.
7. Devenny DA, Hill AL, Patxot O, Silverman WP, Wisniewski KE. Ageing in higher functioning adults with Down's syndrome: an interim report in a longitudinal study. J Intellect Disabil Res. 1992;36(pt 3):241-250.
8. Zigman WB, Schupf N, Urv T, Zigman A, Silverman W. Incidence and temporal patterns of adaptive behavior change in adults with mental retardation. Am J Ment Retard. 2002;107(3):161-174.
9. Moncaster JA, Pineda R, Moir RD, et al. Alzheimer's disease amyloid-β links lens and brain pathology in Down syndrome. PLoS One. 2010;5(5):e10659.
10. Clark CM, Schneider JA, Bedell BJ, et al.; AV45-A07 Study Group. Use of florbetapir- PET for imaging β-amyloid pathology [published correction appears in JAMA. 2011;305(11):1096]. JAMA. 2011;305(3):275-283.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
12. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
13. Lengyel Z, Balogh E, Emri M, et al. Pattern of increased cerebral FDG uptake in Down syndrome patients. Pediatr Neurol. 2006;34(4):270-275.
14. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56(10):1095- 1097.
15. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(pt 6):1630-1645. (Pubitemid 351806448)
16. Haier RJ, Head K, Head E, Lott IT. Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage. 2008;39(3):1324-1332.
17. Head E, Lott IT, Patterson D, Doran E, Haier RJ. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. J Alzheimers Dis. 2007;11(1):61-76. (Pubitemid 46376710)
18. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. (Pubitemid 38269583)
19. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer's disease using the radioligand 18F-AV-45 (florbetapir F 18) [published correction appears in J Nucl Med. 2010;51(8):1327]. J Nucl Med. 2010; 51(6):913-920.